6-Chloro-4-methoxy-3-methylpyridazine | 528878-33-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Chloro-4-methoxy-3-methylpyridazine
• CAS: 528878-33-3
• 化学式: C₆H₇ClN₂O
• mdl: MFCD09907996
• 分子量: 158.58
• InChiKey: XNALUGIAHDILBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：Conn P. Jeffrey

  公开号：US20120225844A1

  公开（公告）日：2012-09-06

  In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及双环三唑和吡唑内酰胺、其衍生物和相关化合物，可作为代谢型谷氨酸受体亚型5（mGluR5）的正向变构调节剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，不限制本发明。
• Pyridone, pyridazone and triazone derivatives as lp-pla2 inhibitors
  申请人：Fell Christopher Martin Stephen

  公开号：US20050020832A1

  公开（公告）日：2005-01-27

  Compounds of the formula (I) are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.

  式（I）化合物是 Lp-PLA2 酶的抑制剂，可用于治疗，尤其是治疗动脉粥样硬化。
• PYRIDONE, PYRIDAZONE AND TRIAZONE DERIVATIVES AS LP-PLA2 INHIBITORS
  申请人：SmithKline Beecham P.L.C.

  公开号：EP1441731A1

  公开（公告）日：2004-08-04
• [EN] PYRIDONE, PYRIDAZONE AND TRIAZONE DERIVATIVES AS LP-PLA2 INHIBITORS<br/>[FR] DERIVES DE PYRIDONE, PYRIDAZONE ET TRIAZONE EN TANT QU'INHIBITEURS DE LP-PLA2
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2003041712A1

  公开（公告）日：2003-05-22

  Compounds of the formula (I) are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.